Feline immunodeficiency virus model for designing HIV/AIDS vaccines

Current HIV Research

Volumn 8, Issue 1, 2010, Pages 14-25

  Yamamoto, Janet K ^a   Sanou, Missa P ^a   Abbott, Jeffrey R ^a   Coleman, James K ^a  

^a University of Florida College of Veterinary Medicine   (United States)

Author keywords

AIDS; Animal model; FIV; Vaccine

Indexed keywords

FELINE LEUKEMIA VIRUS VACCINE; HUMAN IMMUNODEFICIENCY VIRUS VACCINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; CAT; DRUG DESIGN; DRUG EFFICACY; DRUG SAFETY; FELINE IMMUNODEFICIENCY VIRUS; LENTIVIRINAE; NONHUMAN; NUCLEOTIDE SEQUENCE; PROPHYLAXIS; REVIEW; UNINDEXED SEQUENCE; UNITED STATES; VETERINARY MEDICINE; VIRUS INFECTION; VIRUS TYPING;

AIDS VACCINES; ANIMALS; CATS; DISEASE MODELS, ANIMAL; DRUG DESIGN; EPITOPES; FELINE ACQUIRED IMMUNODEFICIENCY SYNDROME; HUMANS; IMMUNIZATION, PASSIVE; IMMUNODEFICIENCY VIRUS, FELINE; PHYLOGENY; VIRAL VACCINES;

EID: 77949678848     PISSN: 1570162X     EISSN: None     Source Type: Journal    
DOI: 10.2174/157016210790416361     Document Type: Review

References (72)

1. Pedersen NC, Ho EW, Brown ML, Yamamoto JK. Isolation of a T-lymphotropic virus from domestic cats with an immunodeficiency-like syndrome. Science 1987; 235: 790-3.
2. rd Ed, Elsevier Ltd, Oxford, UK 2008; pp. 347-54.
3. Yamamoto JK, Pu R, Sato E, Hohdatsu T. Feline immunodeficiency virus pathogenesis and development of a dual-subtype feline-immunodeficiency-virus vaccine. AIDS 2007; 21: 547-63.
4. Geretti AM. HIV-1 subtypes: epidemiology and significance for HIV management. Curr Opin Infect Dis 2006; 19: 1-7.
5. Reggeti F, Bienzle D. Feline immunodeficiency virus subtypes A, B and C and intersubtype recombinants in Ontario, Canada. J Gen Virol 2004; 85: 1843-52.
6. Hayward JJ, Rodrigo AG. Recombination in feline immunodeficiency virus from feral and companion domestic cats. Virol J 2008; 5: 76.
7. Bachmann MH, Mathiason-Dubard C, Learn GH, et al. Genetic diversity of feline immunodeficiency virus: dual infection, recombination, and distinct evolutionary rates among envelope sequence clades. J Virol 1997; 71: 4241-53.
8. English RV, Johnson CM, Gebhard DH, Tompkins MB. In vivo lymphocyte tropism of feline immunodeficiency virus. J Virol 1993; 67: 5175-86.
9. Tanabe T, Yamamoto JK. Phenotypic and functional characteristics of FIV infection in the bone marrow stroma. Virology 2001; 282: 113-22.
10. Salek-Ardakani S, Croft M. Regulation of CD4 T cell memory by OX40 (CD134). Vaccine 2006; 24: 872-83.
11. Willett BJ, McMonagle EL, Logan N, Spiller OB, Schneider P, Hosie MJ. Probing the interaction between feline immunodeficiency virus and CD134 by using the novel monoclonal antibody 7D6 and the CD134 (Ox40) ligand. J Virol 2007; 81: 9665-79.
12. Reggeti F, Ackerley C, Bienzle D. CD134 and CXCR4 expression corresponds to feline immunodeficiency virus infection of lymphocytes, macrophages and dendritic cells. J Gen Virol 2008; 89: 277-87.
13. Yamamoto JK, Hansen H, Ho EW, et al. Epidemiologic and clinical aspects of feline immunodeficiency virus (FIV) infection in cats from the continental United States and Canada and possible mode of transmission. J Am Vet Med Assoc 1989; 194: 213-20.
14. Boudreaux CE, Lockett NN, Chemerys DN, et al. Maternal hematological and virological characteristics during early feline immunodeficiency virus (FIV) infection of cats as predictors of fetal infection and reproductive outcome at early gestation. Vet Immunol Immunopathol 2009; 19. doi:10.1016/j.vetimm.2009.04. 011 [Epub ahead of print].
15. Burkhard MJ, Dean GA. Transmission and immunopathogenesis of FIV in cats as a model for HIV. Curr HIV Res 2003; 1: 15-29.
16. Allison RW, Hoover EA. Feline immunodeficiency virus is concentrated in milk early in lactation. AIDS Res Hum Retrovir 2003; 19: 245-53.
17. O'Neil LL, Burkhard MJ, Hoover EA. Frequent perinatal transmission of feline immunodeficiency virus by chronically infected cats. J Virol 1996; 70: 2894-901.
18. Arai M, Earle D, Yamamoto JK. Is AZT/3TC therapy effective against FIV infection or immunopathogenesis? Vet Immunol Immunopath 2002; 85: 189-204.
19. Hartmann K, Ferk G, North TW, Pedersen NC. Toxicity associated with high dosage 9-[(2R,5R-2,5-dihydro-5-phosphonomethoxy)-2-furanyl]adenine therapy off attempts to abort early FIV infection. Antiviral Res 1997; 36: 11-25.
20. Norelli S, El Daker S, D'Ostilio D, et al. Response of feline immunodeficiency virus (FIV) to tipranavir may provide new clues for development of broad-based inhibitors of retroviral proteases acting on drug-resistant HIV-1. Curr HIV Res 2008; 6: 306-17.
21. Savarino A, Pistello M, D'Ostilio D, et al. Human immunodeficiency virus integrase inhibitors efficiently suppress feline immunodeficiency virus replication in vitro and provide a rationale to redesign antiretroviral treatment for feline AIDS. Retrovirology 2007; 4: 79.
22. Willett BJ, Hosie MJ, Dunsford TH, Neil JC, Jarrett O. Productive infection of T-helper lymphocytes with feline immunodeficiency virus is accompanied by reduced expression of CD4. AIDS 1991; 5: 1469-75.
23. Dow SW, Poss ML, Hoover EA. Feline immunodeficiency virus: a neurotropic lentivirus. J Acquir Immune Defic Syndr 1990; 3: 658-68.
24. Bendinelli M, Pistello M, Lombardi S, et al. Feline immunodeficency virus: an interesting model for AIDS studies and an important cat pathogen. Clin Microbiol Rev 1995; 8: 87-112.
25. Siebelink KHJ, Chu I-H, Rimmelzwaan GF, et al. Feline immunodeficiency virus (FIV) infection in the cat as a model for HIV infection in man: FIV-induced impairment of immune function. AIDS Res Hum Retroviruses 1990; 6: 1373-8.
26. Hofmann-Lehmann R, Holznagel E, Ossent P, Lutz H. Parameters of disease progression in long-term experimental feline retrovirus (feline immunodeficiency virus and feline leukemia virus) infections: hematology, clinical chemistry, and lymphocyte subsets. Clin Diagn Lab Immunol 1997; 4: 33-42.
27. Olmsted RA, Hirsch VM, Purcell RH, Johnson PR. Nucleotide sequence analysis of feline immunodeficiency virus: genome organization and relationship to other lentiviruses. Proc Natl Acad Sci USA 1989; 86: 8088-92.
28. Talbott RL, Sparger EE, Lovelace KM, et al. Nucleotide sequence and genomic organization of feline immunodeficiency virus. Proc Natl Acad Sci USA 1989; 86: 5743-7.
29. Yamamoto JK, Ackley CD, Zochlinski H, et al. Development of IL 2 independent feline lymphoid cell lines chronically infected with feline immunodeficiency virus: importance for diagnostic reagents and vaccines. Intervirol 1991; 32: 361-75.
30. Elyar J, Tellier MC, Soos JM, Yamamoto JK. Perspectives on FIV vaccine development. Vaccine 1997; 15: 1437-44.
31. Uhl EW, Heaton-Jones T, Pu R, Yamamoto JK. FIV vaccine development and its importance to veterinary and human medicine: a review. Vet Immunol Immunopath 2002; 90: 113-32.
32. Hosie MJ, Dunsford T, Klein D, et al. Vaccination with inactivated viruses but not viral DNA reduces virus load following challenge with a heterologous and virulent isolate of feline immunodeficiency virus. J Virol 2000; 74: 9403-11.
33. Cuisinier AM, Meyer A, Chatrenet B, Verdier AS, Aubert A. Attempt to modify the immune response developed against FIV gp120 protein by preliminary FIV DNA injection. Vaccine 1999; 17: 415-25.
34. Tellier MC, Pu R, Pollock D, et al. Efficacy evaluation of prime/boost protocol: Canarypox-based (ALVAC) FIV recombinant and inactivated FIV-cell vaccine against heterologous FIV challenges in cats. AIDS 1998; 12: 11-18.
35. Hesselink W, Sondermeijer P, Pouwels H, Verblakt E, Dhore C. Vaccination of cats against feline immunodeficiency virus (FIV): a matter of challenge. Vet Microbiol 1999; 69: 109-110.
36. Yamamoto JK, Pu R, Sato E, Hohdatsu T. Feline immunodeficiency virus pathogenesis and development of a dual-subtype feline-immunodeficiency-virus vaccine. AIDS 2007; 21: 547-63.
37. Siebelink KHJ, Tijhaar E, Huisman RC. Enhancement of feline immunodeficiency virus infection after immunization with envelope glycoprotein subunit vaccines. J Virol 1995; 69: 3704-11.
38. Karlas JA, Siebelink KH, Peer MA, et al. Vaccination with experimental feline immunodeficiency virus vaccines, fixed autologous infected cells, elicits enhancement of homologous challenge infection. J Gen Virol 1999; 80: 761-5.
39. Matteucci D, Poli A, Mazzetti P, et al. Immunogenicity of an anticlade B feline immunodeficiency fixed-cell virus vaccine in field cats. J Virol 2000; 74: 10911-9.
40. Matteucci D, Pistello M, Mazzetti P, et al. AIDS vaccination studies using feline immunodeficiency virus as a model: immunization with inactivated virus suppress viraemia levels following intravaginal challenge with cell-free virus. Vaccine 1999; 18: 119-30.
41. Omori M, Pu R, Tanabe T, et al. Cellular immune responses to feline immunodeficiency virus (FIV) induced by dual-subtype FIV vaccine. Vaccine 2004; 23: 386-98.
42. Uhl, EW, Martin M, Coleman J, Yamamoto JK. Advances in FIV vaccine technology. Vet Immunol Immunopath 2008; 123: 65-80.
43. Pu R, Coleman J, Omori M, et al. Dual-subtype FIV vaccine protects cats against in vivo swarms of both homologous and heterologous subtype FIV isolates. AIDS 2001; 15: 1-13.
44. Enioutina EY, Visic D, Daynes RA. The induction of systemic and mucosal immune responses to antigen-adjuvant composition administered into the skin: alterations in the migratory properties of dendritic cells appear to be important for stimulating mucosal immunity. Vaccine 2000; 18: 2753-67.
45. Belyakov IM, Berzofsky JA. Immunobiology of mucosal HIV infection and the basis for development of a new generation of mucosal AIDS vaccines. Immunity 2004; 20: 247-53.
46. Levy JK, Crawford PC, Kusuhara H, et al. Differentiation of feline immunodeficiency virus vaccination, infection, or vaccination and infection in cats. J Vet Intern Med 2008; 22: 330-4.
47. Hoover EA, Perigo NA, Quackenbush SL, et al. Protection against feline leukemia virus infection by use of an inactivated virus vaccine. J Am Vet Med Assoc 1991; 199: 1392-401.
48. Huang C, Conlee D, Loop J, Champ D, Gill M, Chu HJ. Efficacy and safety of a feline immunodeficiency virus vaccine. Anim Health Res Rev 2004; 5: 295-300.
49. Kusuhara H, Hohdatsu T, Okumura M, et al. Dual-subtype vaccine (Fel-O-Vax FIV) protects cats against contact challenge with heterologous subtype B FIV infected cats. Vet Microbiol 2005; 108: 155-65.
50. Yamamoto JK, Sato E, Pu R, Coleman J, Martin M. Feline immunodeficiency virus vaccines: Evolving concepts on a vaccine approaches. Cellscience Reviews Vol. 2, No. 3, Jan. 2006, (http://cellscience.com/reviews7/Yamamoto.pdf) (Accessed 21 July 2009).
51. Pu R, Sato E, Coisman J, et al. Dual-subtype FIV vaccine (Fel-O-Vax® FIV) protection against heterologous subtype B FIV isolate. Feline Med Surgery 2005; 7: 65-70.
52. Dunham SP. Lessons from the cats: Development of vaccines against lentiviruses. Vet Immunol Immunopathol 2006; 112: 67-77.
53. Dunham SP, Bruce J, MacKay S, Golder M, Jarrett O, Neil JC. Limited efficacy of an inactivated feline immunodeficiency virus vaccine. Vet Rec 2006; 158: 561-2.
54. Kann RK, Kyaw-Tanner MT, Seddon JM, Lehrbach PR, Zwijnenberg RJ, Meers J. Molecular subtyping of feline immunodeficiency virus from domestic cats in Australia. Aust Vet J 2006; 84: 112-6.
55. Nishimura Y, Goto Y, Pang H, et al. Genetic heterogeneity of env gene of feline immunodeficiency virus obtained from multiple districts in Japan. Virus Res 1998; 57: 101-12.
56. Lombardi S, Garzelli C, La Rosa C, et al. Identification of a linear neutralization site within the third variable region of the feline immunodeficiency virus envelope. J Virol 1993; 67: 4742-9.
57. de Ronde A, Stam JG, Boers P, et al. Antibody response in cats to the envelope proteins of feline immunodeficiency virus: identification of an immunodominant neutralization domain. Virology 1994; 198: 257-64.
58. Siebelink KH, Huisman W, Karlas JA, Rimmelzwaan GF, Bosch ML, Osterhaus AD. Neutralization of feline immunodeficiency virus by polyclonal feline antibody: simultaneous involvement of hypervariable regions 4 and 5 of the surface glycoprotein. J Virol 1995; 69: 5124-7.
59. Hosie MJ, Klein D, Binley JM, et al. Vaccination with an inactivated virulent feline immunodeficiency virus engineered to express high levels of Env. J Virol 2005; 79: 1954-7.
60. Zolla-Pazner S. Identifying epitopes of HIV-1 that induce protective antibodies. Nat Rev Immunol 2004; 4: 199-210.
61. Richardson J, Moraillon A, Crespeau F, Baud S, Sonigo P, Pancino G. Delayed infection after immunization with a peptide from the transmembrane glycoprotein of the feline immunodeficiency virus. J Virol 1998; 72: 2406-15.
62. DeRonde A, Stam JG, Boers P, et al. Antibody response in cats to the envelope proteins of feline immunodeficiency virus: identification of an immunodominant neutralization domain. Virology 1994; 198(1): 257-64.
63. Coleman JK, Pu R, Martin M, Sato E, Yamamoto JK. HIV-1 p24 vaccine protects cats against FIV. AIDS 2005; 19: 1457-66.
64. Hosie MJ, Osborne R, Reid G, et al. Enhancement after feline immunodeficiency virus vaccination. Vet Immunol Immunopathol 1992; 35: 191-7.
65. Marsh SGE, Parham P, Barber LD. In: The HLA Facts Book. Academic Press, New York, 2000; pp. 5-78.
66. Los Alamos National Laboratory. HIV molecular immunology database: epitope maps (http://www.hiv.lanl.gov/content/immunology/maps/maps.html).
67. Yuhki N, Mullikin JC, Beck T, Stephens R, O'Brien SJ. Sequences, annotation and single nucleotide polymorphism of the major histocompatibility complex in the domestic cat. PLoS One 2008; 3(7): e2674.
68. Kennedy LJ, Ryvar R, Brown JJ, Ollier WER, Radford AD. Resolution of complex feline leukocyte antigen DRB loci by reference strand-mediated conformation analysis (RSCA). Tissue Antigens 2003; 62: 313-23.
69. Marsh SGE, Parham P, Barber LD. In: The HLA Facts Book. Academic Press, New York, 2000; pp. 93-376.
70. Troyer JL, Pecon-Slattery J, Roelke ME, et al. Seroprevalence and genomic divergence of circulating strains of feline immunodeficiency virus among Felidae and Hyaenidae species. J Virol 2005; 79: 8282-94.
71. Saitou N, Nei M. The neighbor-joining method: a new method for reconstructing phylogenetic trees. Mol Biol Evol 1987; 4: 406-35.
72. Kimura M. A simple method for estimating evolutionary rates of base substitution through comparative studies of nucleotide sequences. J Mol Evol 1980; 16: 111-20.